Acutus Medical – maker of 3-D imaging technology for heart procedures – on June 20 netted $170 million.
The financing, $100 million from a Series D round and $70 million in credit, will quicken commercialization, according to the Carlsbad company.
The company’s flagship product, AcQMap, creates a virtual map of the heart chamber. This aids doctors performing cardiac ablation, used to treat an irregular heartbeat, or arrhythmia.
The most common type of arrhythmia, called atrial fibrillation, affects an estimated 2.7 million to 6.1 million Americans, according to the Centers for Disease Control and Prevention. The agency said the number is expected to increase with an aging population.
In 2017, AcQMap won U.S. Food and Drug Administration approval, preceded by the regulatory green light in the European Union.
The prior year, Acutus hauled in a $75 million Series C round.
This latest round included new investors 8VC, Opaleye Management and Pura Vida Investments, among others. Also participating were existing investors OrbiMed, Deerfield Management Co., Advent Venture Partners, Xeraya Capital and GE Ventures.
OrbiMed Credit, Royalties Fund and Deerfield Management provided the $70 million loan.